Work

LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.088

Authors: H. Grönberg, J. Lindberg, B. De Laere, A. Crippa, A. Discacciati, C.T. Karlsson, A. Ullén, E. Jänes, A. Mortezavi, P. Ost, G. Enblad, J. Oldenburg, J. Sandzén, L. Pettersson, M.N. Vigmostad, M.E. Hjälm-Eriksson, M. Olsson, P. Schatteman, C. Ghysel, M. Eklund

Institutions: Karolinska Institutet, Umeå University, Karolinska University Hospital, Sundsvall Municipality, Länssjukhuset Sundsvall-Härnösand, University Hospital of Basel, Ghent University Hospital, Uppsala University Hospital, Akershus University Hospital, Karlstad Central Hospital, Ryhov Hospital Jönköping, Stavanger University Hospital, Saint Göran Hospital, Onze Lieve Vrouwziekenhuis Hospital, AZ Sint-Jan

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387809579

Cites:

Cited by: 1

Related to: 10